Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
Gina Mauro
Advertisement
Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Articles by Gina Mauro
The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.
The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
5
